Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI306 in Homozygous Familial Hypercholesterolemia (China)
CTR20191429Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in familial hypercholesterolemia (FH), sponsored by Innovent Biologics. Started Jul 2019; status: completed.
02
Drugs
tafolecimab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20191429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191429.